Total R&D costs including costs of capital for select cancer drugs 2017

Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017 (in million U.S. dollars)

Total R&D costs including costs of capital for select cancer drugs 2017 This statistic shows the total cost of research and development (R&D) including a 7 percent per annum cost of capital for select cancer drugs that were on the market as of 2017. Alexion Pharmaceuticals' drug Eculizumab had a total R&D cost, including capital, of around 1.09 billion U.S. dollars as of 2017. Total R&D costs without the 7 percent of annual cost of capital stood at some 818 million dollars.
Show more

Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017 (in million U.S. dollars)

Loading statistic...
Drug name (company, R&D start date)Cost in million U.S. dollars
Cabozantinib
(Exelixis, 01/2004)
2,601.7
Ruxolitinib
(Incyte Corp., 01/2004)
1,374.3
Brentuximab vedotin
(Seattle Genetics, 01/2001)
1,119.2
Eculizumab
(Alexion Pharm., 01/1992)*
1,088
Irinotecan liposome
(Merrimack Pharm., 12/2009)**
959.8
Enzalutamide
(Medivation, 08/2005)**
554.9
Ponatinib
(Ariad Pharm., 01/2007)
548.4
Ibrutinib
(Pharmacyclics, 04/2006)**
388.7
Pralatrexate
(Allos Therap., 12/2002)**
217.4
Vincristine liposome
(Talon Therap., 05/2006)**
203.6
Drug name (company, R&D start date)Cost in million U.S. dollars
Cabozantinib
(Exelixis, 01/2004)
2,601.7
Ruxolitinib
(Incyte Corp., 01/2004)
1,374.3
Brentuximab vedotin
(Seattle Genetics, 01/2001)
1,119.2
Eculizumab
(Alexion Pharm., 01/1992)*
1,088
Irinotecan liposome
(Merrimack Pharm., 12/2009)**
959.8
Enzalutamide
(Medivation, 08/2005)**
554.9
Ponatinib
(Ariad Pharm., 01/2007)
548.4
Ibrutinib
(Pharmacyclics, 04/2006)**
388.7
Pralatrexate
(Allos Therap., 12/2002)**
217.4
Vincristine liposome
(Talon Therap., 05/2006)**
203.6
Download Settings Share
Download started
Please be patient - this may take a moment
This statistic shows the total cost of research and development (R&D) including a 7 percent per annum cost of capital for select cancer drugs that were on the market as of 2017. Alexion Pharmaceuticals' drug Eculizumab had a total R&D cost, including capital, of around 1.09 billion U.S. dollars as of 2017. Total R&D costs without the 7 percent of annual cost of capital stood at some 818 million dollars.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Oncology"
  • Cancer facts
  • Oncology market
  • Companies
  • Cancer drugs
  • Research and development
The most important statistics
  • Immuno-oncology
  • Treatment types
  • Physicians and patients
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.